Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

361.36 +2.10 (+0.58%)
Streaming Delayed Price Updated: 11:47 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
News headline image
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why Is Alnylam (ALNY) Stock Up 50% Today? ↗
ALNY stock is quickly moving higher as Wall Street weighs Alnylam's encouraging results for a hard-to-treat condition. 
Via InvestorPlace
News headline image
Expert Ratings for Alnylam Pharmaceuticals ↗
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
News headline image
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug ↗
The company will compete with Pfizer, which already has an approved drug. 
Via Investor's Business Daily
News headline image
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients. 
Via Investor's Business Daily
News headline image
Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) brought in sales totaling $224.82 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 15.42%, resulting in a loss of $277.40... 
Via Benzinga
News headline image
Moderna, PayPal And Some Other Big Gainers From Wednesday ↗
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
  
Via Benzinga
News headline image
What Is Going on With Helius Medical (HSDT) Stock Today? ↗
Helius Medical (HSDT) stock is rocketing higher on Wednesday despite a lack of news from the medical device holding company. 
Via InvestorPlace
News headline image
Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics ↗
Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. 
Via Benzinga
News headline image
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why ↗
Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study. 
Via Investor's Business Daily
News headline image
Why Alnylam Pharma Shares Are Trading Higher During Premarket Session ↗
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Alnylam Pharmaceuticals: Q2 Earnings Insights ↗
  Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine ↗
 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.